January 26, 2001
The preventive vaccine candidate is based upon subtype A of HIV, the most common strain in East Africa. The vaccine candidate is the product of an International AIDS Vaccine Initiative-funded partnership between the research teams of the Medical Research Council's Human Immunology Unit at Oxford University in the United Kingdom and the University of Nairobi.
It will be tested in a new, state of the art research facility at the University of Nairobi, which was officially opened by Kenya's Minister of Public Health, the Hon. Professor Sam K. Ongeri, in December. Recruitment for the trial began in December, and several of the 18 volunteers needed for the Phase I trial have already been screened.
The partners also announced a new agreement under which all existing and future patents covering the vaccine candidate will be owned jointly by the Medical Research Council, the University of Nairobi and the International AIDS Vaccine Initiative (IAVI). The partners agreed to use their patent ownership to help ensure access to a successful AIDS vaccine in Kenya and in other developing countries.
Copyright 2001 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
ISSN # 1052-4207
Back to the AIDS Treatment News January 26, 2001 contents page.